Ultragenyx Pharmaceutical | RARE - Selling And Administration Expenses


Ultragenyx Pharmaceutical reported $88M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Immunic USD 3.45M 451K Dec/2025
Insmed USD 247.26M 34.78M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Kyowa Hakko Kirin JPY 41.07B 2.82B Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Moderna USD 173M 135M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026
Xoma USD 11M 2.54M Jun/2024